📊 Note: Daily ratings and analytics are updated after market close and will be available by 7:00 PM IST.

Details

NameSymbolSector
SEQUENT SCIENTIFIC LIMITEDSEQUENTPharmaceuticals
Open
203.9
High
211
Low
202
Close
207.35
Volume
24821
Exchange
bse
Time
23-Jan-2026

Outlook

Score:

1

Rating:

RISKY

Candlestick Pattern

CandlepatternofSequentScientificis
None
EstimatedStoplossofSequentScientificis
202
SequentScientifichasa
Bullishℹ
pattern.
Formationof
None
candlepatternindicatesthetrenddirectionofSequentScientificis
Unpredictableℹ
.

Trend

SequentScientificisin
Sideways trendℹ
.
PriceofSequentScientificis
Downℹ
by

0.46

%.
Target
Buy@

186.97

Sell@

239.93

Current@

207.35

Volume

ThetradevolumesofSequentScientifichavebecome
Deficientℹ
ThevolumetrendforSequentScientificis
Bearishℹ
,buttheparticipantsare
Weak Sellersℹ
ThetradevolumeofSequentScientificis

Down

by

98.32

%

Valuation

ThecurrentmarketpriceofSequentScientificis
Overvaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth1601crandtotalassetsworth1601cr,thebalancesheetofSequentScientificis:
Balancedℹ
.
Cashflow
SequentScientifichas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 2cr

.Itis
Downℹ
by

108.7

%.
49.7% i.e. ₹ 83cr earned in operatingℹ
14.37% i.e. ₹ 24cr spent in investingℹ
35.93% i.e. ₹ 60cr spent in financingℹ
0% in otherℹ
SequentScientifichas
Maintainedℹ
cashflowbecausethereis

Surplus

of

₹ 23cr

.Itis
Upℹ
by

253.33

%.
83.33% i.e. ₹ 30cr earned in operatingℹ
13.89% i.e. ₹ 5cr spent in investingℹ
2.78% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Income
TheincomeofSequentScientificis

₹ 426cr

and

Profit

is:

₹ 19cr

SequentScientificProfitisupby:

11.76

%andIncomeisDownby:

4.27

%
TheincomeofSequentScientificis

₹ 445cr

and

Profit

is:

₹ 17cr

SequentScientificProfitisupby:

70

%andIncomeisUpby:

10.42

%
TheincomeofSequentScientificis

₹ 403cr

and

Profit

is:

₹ 10cr

SequentScientificProfitisupby:

66.67

%andIncomeisUpby:

1.77

%
By using this site you agree to the use of cookies to deliver a better site experience.